Core binding factor (CBF) acute myeloid leukemias (AML) include AMLs carrying the t(8;21)
translocation as well as AMLs carrying either the inversion of chromosome 16 or translocation
t(16;16). CBF-AMLs are characterized by their high sensitivity to standard chemotherapeutical
agents, especially to cytarabine when administered as high-dose bolus infusions, and thus by
a relative good prognosis. However, relapse rates are still comprised between 30 and 50% in
these patients, even if overall survival may reach approximately 65% due to the potential
salvage of late relapses.
The primary purpose of the protocol is to compare two modalities of timed-sequential
induction in order to improve the results of the treatment of CBF-AML patients. This protocol
also includes the biological characterization of the heterogeneity of these diseases (gene
mutation and transcription profiles), as well as a centralized minimal residual disease
monitoring and centralized evaluation of pharmacogenetic polymorphisms.
Phase:
Phase 3
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborators:
Acute Leukemia French Association French Innovative Leukemia Organisation